US 2021/0059997 A1Published application

Prophylactic agent and/or therapeutic agent for cataract, medicinal composition for preventing and/or treating cataract, use of ppar activator for producing same, and eyedrops

AssigneesUniversity of Fukui, Santen Pharmaceutical Co., Ltd.

InventorsMasaya OKI, Fumito KANADA, Kazuma KAMATA, Yoshihiro TAKAMURA, Seiji MIYAKE, Masaru INATANI, Hiroyuki UCHIDA, Miho NOGATA, Masatomo KATO, Koushi FUJISAWA, Shinji TAKAOKA

Life of this patent

Estimating the term…

patentgrep

Loading patent…

Abstract

Provided are agents for prevention and therapeutic treatment of cataract that act by a different mechanism from conventional agents, and use of a PPAR activator for production of such agents. An agent for prevention and/or therapeutic treatment of cataract, containing a PPAR activator as an active ingredient, is used.

Claims9

Dependent claims

1-27. (canceled)

Dependencies are inferred from the claim text.

Facts

Application: 16/958,571Filed 27 Dec 2018
Priority: JP 2017-25461428 Dec 2017
Published: 4 Mar 2021
Term ends: Not estimatedThe source records don’t support an estimate.

Classification9 codes

A61K 31/4439
Containing further heterocyclic ring systems: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61P 3/10
For glucose homeostasis: for hyperglycaemia, e.g. antidiabetics
A61K 9/0048
Galenical forms characterised by the site of application: eye, e.g. artificial tears
A61K 31/192
Carboxylic acids, e.g. valproic acid: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid